LDH-A Antibody (5): sc-130327
- LDH-A Antibody (5) is a mouse monoclonal IgG1 κ, cited in 7 publications, provided at 200 µg/ml
- raised against recombinant LDH-A of human origin
- recommended for detection of LDH-A of human origin by WB, IP and ELISA
- See LDH-A (E-9): sc-137243 for LDH-A antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for LDH-A Antibody (5). This work is in progress.
LDH-A Antibody (5) is a mouse monoclonal IgG1 antibody that detects lactate dehydrogenase A (LDH-A) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). LDH-A plays a crucial role in cellular metabolism by catalyzing the conversion of L-lactate to pyruvate, a key step in anaerobic glycolysis, which is vital for energy production, especially in tissues with high energy demands like muscle. LDH-A serves as a significant biomarker for various conditions, including germ cell tumors, where expression levels can indicate tumor presence and progression. LDH-A is predominantly expressed in muscle tissue, highlighting a role in energy production during intense physical activity. The gene encoding LDH-A is located on chromosome 11, and mutations or deficiencies in this gene can lead to conditions such as exertional myoglobinuria, underscoring LDH-A′s importance in both health and disease. Anti-LDH-A antibody (5) is an essential tool for researchers studying metabolic pathways and cancer biology, providing reliable detection and quantification of this critical enzyme.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
LDH-A Antibody (5) References:
- LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response. | Serganova, I., et al. 2018. PLoS One. 13: e0203965. PMID: 30248111
- LDH-A promotes malignant behavior via activation of epithelial-to-mesenchymal transition in lung adenocarcinoma. | Hou, XM., et al. 2019. Biosci Rep. 39: PMID: 30509961
- Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma. | Daneshmandi, S., et al. 2019. Cancers (Basel). 11: PMID: 30934955
- LDH-A negatively regulates dMMR in colorectal cancer. | Zhang, Y., et al. 2021. Cancer Sci. 112: 3050-3063. PMID: 34110068
- LDH-A inhibitors as remedies to enhance the anticancer effects of PARP inhibitors in ovarian cancer cells. | Xiang, J., et al. 2021. Aging (Albany NY). 13: 25920-25930. PMID: 34919531
- LDH-A-Modulation and the Variability of LDH Isoenzyme Profiles in Murine Gliomas: A Link with Metabolic and Growth Responses. | Shindo, M., et al. 2022. Cancers (Basel). 14: PMID: 35565432
- Genetic and Drug Inhibition of LDH-A: Effects on Murine Gliomas. | Maeda, M., et al. 2022. Cancers (Basel). 14: PMID: 35565435
- Blockade of KLF5/LDH-A feedback loop contributes to Curcumol inhibition of sinusoidal endothelial cell glycolysis and mitigation of liver fibrosis. | Li, Y., et al. 2023. Phytomedicine. 114: 154759. PMID: 37031640
- Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1α transcriptional complex. | Wang, F., et al. 2024. Hepatology. 79: 606-623. PMID: 37733267
- LDH-A Inhibitor as a Remedy to Potentiate the Anticancer Effect of Docetaxel in Prostate Cancer. | Cakici, C., et al. 2024. J Cancer. 15: 590-602. PMID: 38213726
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LDH-A Antibody (5) | sc-130327 | 200 µg/ml | $322.00 |